New approaches to rapidly control foot-and-mouth disease outbreaks

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 4, 2003, Pages 579-586

  Grubman, Marvin J ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

Adenovirus vector; Foot and mouth disease; Type I interferon; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; FOOT AND MOUTH DISEASE VACCINE; GAMMA INTERFERON; VIRUS VECTOR;

DISEASE TRANSMISSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; ECONOMIC ASPECT; EPIDEMIC; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; IMMUNITY; INFECTION CONTROL; LIVESTOCK; NONHUMAN; REVIEW; TERRORISM; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 3042781126     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.4.579     Document Type: Review

References (72)

1. Murphy FA. Gibbs EP, Horzinek MC, Studdert MJ. Veterinary Virology. (3rd Edition) Academic Press, NY, USA (1999).
2. Mason PW, Grubman MJ, Baxt B. Molecular basis of pathogenesis of FMDV. In: Foot-and-Mouth Disease. Rowlands D (Ed.). Virus Res. 91, 9-32 (2003).
3. Leforban Y. Prevention measures against foot-and-mouth disease in Europe in recent years. Vaccine 17, 1755-1759 (1999).
4. Brown F. New approaches to vaccination against foot-and-mouth disease. Vaccine 10, 1022-1026 (1992).
5. Doel TR. FMD vaccines. in: Foot-and-Mouth Disease. Rowlands D (Ed.). Virus Res. 91, 81-99 (2003).
6. Correa Melo E, Saraiva V, Astudillo V. Review of the status of foot and mouth disease in countries of South America and approaches to control and eradication. Rev. Sci. Tech. Off. Int. Epiz. 21, 429-436 (2002).
7. Yang PC, Chu RM, Chung WB, Sung HT. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet. Rec. 145, 731-734 (1999).
8. Knowles NJ, Samuel AR, Davies PR, Kitching RP, Donaldson AI. Outbreak of foot-and-mouth disease virus serotype O in the UK caused by a pandemic strain. Vet. Rec. 148, 258-259 (2001).
9. Chmitelin I, Moutou F. Foot-and-mouth disease: lessons to be learned from the experience of France. Rev. Sci. Tech. Off. Int. Epiz. 21, 723-730 (2002).
10. Pluimers FH, Akkerman AM, van der Wal P, Dekker A, Bianchi A. Lessons from the foot and mouth disease outbreak in the Netherlands in 2001. Rev. Sci. Tech. Off. Int. Epiz. 21, 711-721 (2002).
11. Scudamore JM, Harris DM. Control of foot and mouth disease: lessons from the experience of the outbreak in Great Britain in 2001. Rev. Sci. Tech. Off. Int. Epiz. 21, 699-710 (2002).
12. Anon. Infectious disease in livestock. The Royal Society (2002).
13. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263, 496-506 (1999).
14. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19, 2152-2162 (2001).
15. Moraes MP, Mayr GA, Mason PW, Grubman MJ. Early protection against homologous challenge after a single dose of replication-defective human adenovirus Type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639 (2002).
16. Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, Lefevre F, Parkhouse RM. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Virol. 82, 1713-1724 (2001).
17. Sanz-Parra A, Jimenez-Clavero MA, Garcia-Briones MM, Blanco E, Sobrino F, Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 259, 129-134 (1999a).
18. Sanz-Parra A, Vazquez B, Sobrino F, Cox SJ, Ley V, Salt JS. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot -and-mouth disease virus capsid proteins. J. Gen. Virol. 80, 671-679 (1999b).
19. Wang CY, Chang TY, Walfield AM et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20, 2603-2610 (2002).
20. Wong HT, Cheng SC, Chan EW et al. Plasmids encoding foot-and-mouth disease vinis VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 278, 27-35 (2000).
21. Wong HT, Cheng SC, Sin FW, Chan EW, Sheng ZT, Xie Y. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine 20, 2641-2647 (2002).
22. Graves JH, McKercher PD, Farris HE Jr, Cowan KM. Early response of cattle and swine to inactivated foot-and-mouth disease vaccine. Res. Vet. Sci. 9, 35-40 (1968).
23. Sellers RF, Herniman KAJ. Early protection of pigs against foot-and-mouth disease. Br. Vet. J. 130, 440-445 (1974).
24. Doel TR, Williams L, Barnett PV. Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 12, 592-600 (1994).
25. Salt JS, Barnett PV, Dani P, Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 16, 746-754 (1998).
26. Cox SJ, Barnett PV, Dani P, Salt JS. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 17, 1858-1868 (1999).
27. Biron CA, Sen GC. Interferons and other cytokines. In: Field's Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 321-351 (2001).
28. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81, 2341-2364 (2000).
29. Devaney MA, Vakharia VN, Lloyd RE, Ehrenfeld E, Grubman MJ. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap binding protein complex. J. Virol. 62, 4407-4409 (1988).
30. Chinsangaram J, Koster M, Grubman MJ. Inhibition of L-deleted foot-and-mouth disease virus replication by α/β interferon involves double-stranded RNA-dependent protein kinase. J. Virol. 12, 5498-5503 (2001).
31. Chinsangaram J, Piccone ME, Grubman MJ. Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of α/β interferon. J. Virol. 73, 9891-9898 (1999).
32. Piccone ME, Rieder E, Mason PW, Grubman MJ. The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J. Virol. 69, 5376-5382 (1995).
33. Mason PW, Piccone ME, McKenna TS, Chinsangaram J, Grubman MJ. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 227, 96-102 (1997).
34. Chinsangaram J, Mason PW, Grubman MJ. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine 16, 1516-1522 (1998).
35. Brown CC, Piccone ME, Mason PW, McKenna T St-C, Grubman MJ. Pathogenesis of wild type and leaderless foot-and-mouth disease virus in bovines. J. Virol. 70, 5638-5641 (1996).
36. Almeida MR, Rieder E, Chinsangaram J et al. Construction and evaluation of an attenuated vaccine for foot-and-mouth disease; difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus. Virus Res. 55, 49-60 (1998).
37. Chinsangaram J, Moraes MP, Koster M, Grubman MJ. A novel viral disease control strategy: adenovirus expressing interferon α rapidly protects swine from foot-and-mouth disease. J. Virol. 77, 1621-1625 (2003).
38. Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immun. 169, 375-383 (2002).
39. 1 interferon on bovine herpesvirus Type 1-induced respiratory disease. J. Gen. Virol. 66, 2383-2394 (1985).
40. Brooks TJG, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St. Louis encephalitis vinis delivered by the aerosol and subcutaneous routes. Antiviral Res. 41, 57-6A (1999).
41. Lukaszewski RA, Brooks TJG. Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Virol. 74, 5006-5015 (2000).
42. Noisakran S, Campbell IL, Carr DJJ. Ectopic expression of DNA encoding IFN-α1 in the cornea protects mice from herpes simplex virus Type 1-induced encephalitis. J. Immunol. 162, 4184-4190 (1999).
43. Rosenquist BD, Allen GK. Effect of bovine fibroblast interferon on rhinovirus infection in calves. Am. J. Vet. Res. 51, 870-873 (1990).
44. Schwers A, Severin JE, Bublot M et al. Protection of cattle from infection with vaccinia virus by bovine interferon αC. Vet. Rec. 125, 15-16 (1989).
45. Pawlotsky J-M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59, 1-11 (2003).
46. Heintges T, Petry W, Kaldewey M et al. Combination therapy of active HbsAg vaccination and interferon-α in interferon-α nonresponders with chronic hepatitis B. Digest. Dis. Sci. 46, 901-906 (2001).
47. Protzer U, Nassal M, Chiang P-W, Kirschfink M, Schaller H. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild type virus infection. Proc. Natl Acad. Sci. USA 96, 10818-10823 (1999).
48. Salmon P, Le Cotonnec JY, Galazlca A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy mate volunteers. J. Int, Cyt. Res. 16, 759-764 (1996).
49. Qin XQ, Tao N, Dergay A et al. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl Acad. Sci. USA 95, 14411-14416 (1998).
50. Santodonato L, Ferrantini M, Palombo F et al. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther. 8, 63-72 (2001).
51. Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc. Natl Acad. Sci. USA 64, 81-86 (1969).
52. Sellers RF, Herniman KAJ, Leiper JWG, Planterose DN. The effect of double-stranded RNA of fungal origin on the development of foot-and-mouth disease in pigs and calves. Vet. Rec. 93, 90-93 (1973).
53. McVicar JW, Richmond JY, Campbell CH, Hamilton LD. Observations of cattle, goats and pigs after administration of synthetic interferon inducers and subsequent exposure to foot and mouth disease virus. Can. J. Comp. Med. 37, 362-368 (1973).
54. Sellers RF, Herniman KAJ. The effect of synthetic anionic polymer (pyran) on the development of foot-and-mouth disease in guinea-pigs, cattle and pigs. Res. Vet. Sci. 13, 339-341 (1972).
55. Cunliffe HR, Richmond JY, Campbell CH. Interferon inducers and foot-and-mouth disease vaccines: influence of two synthetic polynucleotides on antibody response and immunity in guinea-pigs and swine. Can. J. Comp. Med. 41, 117-121 (1977).
56. Zhang J-F, Hu C, Geng Y et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl Acad. USA 93, 4513-4518 (1996).
57. Aurisicchio L, Delmastro P, Salucci V et al. Liver-specific α 2 interferon gene expression results in protection from induced hepatitis. J. Virol. 74, 4816-4823 (2000).
58. Karaca K, Sharma JM, Winslow BJ et al. Recombinant fowlpox viruses coexpressing chicken Type I IFN and Newcastle disease vinis HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or posthatch administration of recombinant viruses. Vaccine 16, 1496-1503 (1998).
59. Torres JM, Alonso C, Ortega A. Mittal S, Graham F, Enjuanes L. Tropism of human adenovirus Type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J. Virol. 70, 3770-3780 (1996).
60. Prevec L, Schneider M, Rosenthal KL, Belbeck LW, Derbyshire JB, Graham FL. Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 70, 429-434 (1989).
61. Grubman MJ, Mason PW. Prospects, including time-frames, for improved foot-and-mouth disease vaccines. Rev. Sci. Tech. Off. Int. Epiz. 21, 589-600 (2002).
62. Gogev S, Lemaire M, Thiry E. Prevalence of antibodies to human adenovirus Type 5 in Belgian cattle. Vet. Rec. 148, 752-754 (2001).
63. Moraes MP, Chinsangaram J, Brum MCS, Grubman WJ. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon α and a foot-and-mouth disease virus subunit vaccine. Vaccine 22, 268-279 (2003).
64. Wu Q, Brum MCS, Caron L, Koster M, Grubman MJ. Adenovirus-mediated Type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J. Int. Cyt. Res. 23, 2371-2380 (2003).
65. Alexandersen S, Zhang Z, Donaldson AI, Garland AJM. The pathogenesis and diagnosis of foot-and-mouth disease. J. Comp. Path. 129, 1-36 (2003).
66. Zhang ZD, Hutching G, Kitching P, Alexandersen, S. The effects of γ interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Arch. Virol. 147, 2157-2167 (2002).
67. Berger HG, Straub OC, Ahl R, Tesar M, Marquardt O. Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins. Vaccine 8, 213-216 (1990).
68. Bergmann IE, de Mello PA, Neitzert E, Beck E, Gomes I. Diagnosis of persistent aphthovirus infection and its differentiation from vaccination response in cattle by use of enzyme-linked inimunoelectrotransfer blot analysis with bioengineered nonstructural viral antigens. Am. J. Vet. Res. 54, 825-831 (1993).
69. Hohlich BJ, Wiesmuller KH, Schlapp T, Haas B, Pfaff E, Saalmuller A. Identification of foot-and-mouth disease virus-specific linear B-cell epitopes to differentiate between infected and vaccinated cattle. J. Virol. 77, 8633-8639 (2003).
70. Werling D, Jungi TW. TOLL-like receptors linking innate and adaptive immune response. Vet. Immunol. Immunopath. 91, 1-12 (2003).
71. Pontarollo RA, Babiuk LA, Hecker R, van Drunen Little-van den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J. Gen. Virol. 83, 2973-2981 (2002).
72. Baron S, Salazar A, Poast J. Protection by an interferon inducer in an animal model of smallpox: systemic protection does not predict dermal protection. 22nd Annual Meeting of the American Society for Virology. Davis, CA, USA, W1-1, 66 (2003).